Mayne Pharma (ASX: MYX) and Brussels-listed Mithra Pharma announced the launch of HALOETTE, a vaginal hormonal contraceptive ring, into the US market.
HALOETTE is a generic version of NUVARING, a combined hormonal contraceptive flexible ring for the prevention of pregnancy.
According to IQVIA, the maker of NUVARING, sales were approximately $US564 million for the 12 months ended November.
Read Next
For the latest health stocks news, sign up here for free Stockhead daily newsletters
This is another example of our commitment to providing women with more contraceptive choice, said Mayne Pharmas CEO, Shawn OBrien.
Mayne Pharma continues …